CLINUVEL has upgraded its U.S. listing to the Nasdaq exchange under the ticker CUVL to enhance liquidity and visibility. Meanwhile, Rockwell Medical announced it has regained compliance with Nasdaq's minimum bid price requirements. Additionally, Scancell Holdings agreed to an all-share merger with Neuphoria Therapeutics to secure its own Nasdaq listing.
Scancell Holdings agreed to an all-share merger with Neuphoria Therapeutics to secure a Nasdaq listing under ticker SCLT and an $89 million funding package.
Read the full storyRockwell Medical has regained compliance with Nasdaq's minimum bid price rule, removing the immediate threat of delisting after maintaining its share price above the required threshold.
CLINUVEL Pharmaceuticals has moved its U.S. listing to the Nasdaq Global Market to enhance access to institutional and retail investors.